![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
VX-222/Telaprevir in Combination With Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 1 HCV Patients Treated for 12 Weeks: ZENITH Study, SVR12 Interim Analysis
|
|
|
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
David R Nelson*1, Edward J Gane2, Ira M Jacobson3, Adrian M Di Bisceglie4, Katia Alves5, Margaret J Koziel5, Cynthia De Souza5, Tara L Kieffer5, Shelley George5, Maria Rosario5, Robert S Kauffman5, Mark S Sulkowski6
1University of Florida College of Medicine, Gainesville, FL, USA; 2Auckland City Hospital, Auckland, New Zealand; 3Weill Cornell Medical College, New York, NY, USA; 4Saint Louis University School of Medicine, Saint Louis, MO, USA; 5Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 6Johns Hopkins University, Baltimore, MD, USA.
![AASLD1.gif](../images/110911/110911-6/AASLD1.gif)
![AASLD2.gif](../images/110911/110911-6/AASLD2.gif)
![AASLD3.gif](../images/110911/110911-6/AASLD3.gif)
![AASLD4.gif](../images/110911/110911-6/AASLD4.gif)
![AASLD5.gif](../images/110911/110911-6/AASLD5.gif)
![AASLD6.gif](../images/110911/110911-6/AASLD6.gif)
![AASLD7.gif](../images/110911/110911-6/AASLD7.gif)
![AASLD8.gif](../images/110911/110911-6/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|